<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389632</url>
  </required_header>
  <id_info>
    <org_study_id>SGNB6A-001</org_study_id>
    <nct_id>NCT04389632</nct_id>
  </id_info>
  <brief_title>A Study of SGN-B6A in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of SGN-B6A in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will look at a drug called SGN-B6A to find out whether it is safe for people who&#xD;
      have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect&#xD;
      is anything the drug does besides treating cancer. It will also study whether SGN-B6A works&#xD;
      to treat solid tumors.&#xD;
&#xD;
      The study will have two parts. Part A of the study will find out how much SGN-B6A should be&#xD;
      given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A&#xD;
      is and if it works to treat solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (AEs)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Grade 3 or higher AEs</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with serious AEs</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related AEs</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with laboratory abnormalities</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with DLTs</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a DLT at each dose level</measure>
    <time_frame>Up to 21 days after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
    <description>Pharmacokinetic (PK) endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of infusion (Ceoi)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration (Tmax)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with antidrug antibodies</measure>
    <time_frame>Through 30-37 days following last dose of SGN-B6A; up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) per RECIST v1.1</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>The proportion of participants with complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response (DOR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>The time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>The time from the start of any study treatment to the first documentation of disease progression, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>The time from the start of any study treatment to the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Carcinoma, Non-small Cell Lung</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Cutaneous Squamous Cell Cancer</condition>
  <condition>Exocrine Pancreatic Adenocarcinoma</condition>
  <condition>Urinary Bladder Neoplasms</condition>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>SGN-B6A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-B6A monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-B6A</intervention_name>
    <description>Administered into the vein (IV; intravenously)</description>
    <arm_group_label>SGN-B6A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease indication&#xD;
&#xD;
               -  Participants must have histologically or cytologically confirmed metastatic or&#xD;
                  unresectable solid malignancy within one of the tumor types listed below&#xD;
                  (dependent on study part). Participants must have disease that is relapsed or&#xD;
                  refractory or be intolerant to standard-of-care therapies and should have no&#xD;
                  appropriate standard-of-care therapeutic option.&#xD;
&#xD;
          -  Non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Head and neck squamous cell cancer (HNSCC)&#xD;
&#xD;
          -  Advanced HER2-negative breast cancer&#xD;
&#xD;
          -  Esophageal squamous cell carcinoma (ESCC)&#xD;
&#xD;
          -  Cutaneous squamous cell cancer (cSCC)&#xD;
&#xD;
          -  Exocrine pancreatic adenocarcinoma&#xD;
&#xD;
          -  Bladder cancer&#xD;
&#xD;
          -  Cervical cancer&#xD;
&#xD;
          -  Gastric cancer&#xD;
&#xD;
          -  High grade serous ovarian cancer (HGSOC)&#xD;
&#xD;
          -  Participants enrolled in the following study parts should have a tumor site accessible&#xD;
             for biopsy and agree to biopsy as follows:&#xD;
&#xD;
               -  Disease-specific expansion cohorts, participant 13 onwards: pre-treatment biopsy&#xD;
&#xD;
               -  Biology expansion cohort: pre-treatment biopsy and additional on-treatment biopsy&#xD;
                  during Cycle 1&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Measurable disease per the RECIST v1.1 at baseline&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of another malignancy within 3 years before first dose of study drug, or any&#xD;
             evidence of residual disease from a previously diagnosed malignancy. Exceptions are&#xD;
             malignancies with a negligible risk of metastasis or death.&#xD;
&#xD;
          -  Known active central nervous system metastases. Participants with previously treated&#xD;
             brain metastases may participate provided they:&#xD;
&#xD;
               -  are clinically stable for at least 4 weeks prior to study entry after brain&#xD;
                  metastasis treatment,&#xD;
&#xD;
               -  have no new or enlarging brain metastases, and&#xD;
&#xD;
               -  are off of corticosteroids prescribed for symptoms associated with brain&#xD;
                  metastases for at least 7 days prior to first dose of study drug.&#xD;
&#xD;
          -  Carcinomatous meningitis&#xD;
&#xD;
          -  Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6&#xD;
&#xD;
          -  Pre-existing neuropathy Grade 2 or greater per the National Cancer Institute's Common&#xD;
             Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)&#xD;
&#xD;
          -  Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal&#xD;
             infection within 2 weeks prior to the first dose of SGN-B6A.&#xD;
&#xD;
               -  Routine antimicrobial prophylaxis is permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalya Nazarenko, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Poluyanoff</last_name>
      <phone>617-975-7418</phone>
    </contact>
    <investigator>
      <last_name>Bruno Bockorny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Illya Dixon</last_name>
    </contact>
    <investigator>
      <last_name>Khanh Do</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leena Gandhi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kartik Sehgal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadi S Braiteh</last_name>
      <phone>702-952-3400</phone>
    </contact>
    <investigator>
      <last_name>Fadi S Braiteh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edwin C Kingsley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Stamatis</last_name>
      <phone>216-844-7087</phone>
      <email>Stephanie.Stamatis@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Sutcliffe</last_name>
      <phone>503-215-5696</phone>
    </contact>
    <investigator>
      <last_name>Rachel E Sanborn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabia Khan</last_name>
      <phone>713-745-4667</phone>
      <email>RKhan@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sarina A Piha-Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauryn Tuckett</last_name>
      <phone>210-593-5242</phone>
      <email>lauryn.tuckett@startsa.com</email>
    </contact>
    <investigator>
      <last_name>Amita Patnaik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif-Cedex-France</city>
        <state>Other</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine Hollebecque</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Analia Azaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Brana</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Garralda Cabanas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emiliano Calvo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Lausanne CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>Other</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Solange Peters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Other</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juanita S Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>HNSCC</keyword>
  <keyword>cSCC</keyword>
  <keyword>ESCC</keyword>
  <keyword>HGSOC</keyword>
  <keyword>Advanced HER2-Negative Breast Cancer</keyword>
  <keyword>High Grade Serous Ovarian Cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Head and neck squamous cell cancer</keyword>
  <keyword>Esophageal cancer</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

